Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Your best doing your own due diligence Jamrock.
Look at the 5 year charts, read the last 2 years RNSs, and review the November 2023 investormeetcompany presentation by James Cheek.
Don't say you weren't warned about this - when she starts to move she really moves.
- Feb 12th May 2021: GDRs SP was £1.48 (on the back of the Beckman Coulter deal and FDA application for the COVID test, although unfortunately the Americans preferred their own tests).
The difference now is we have world firsts, in the AHIL and Stroke tests operating in a much less saturated market place.
The future is bright.
Stephen11.
At least 100% solstace
RNS as below:
"Zinnwald Lithium plc, the German focused lithium development company, is pleased to announce it has completed a total fundraise of £18.75m at the Placing Price of 10.41p per share pursuant to the Fundraising announced on 22 March 2023."#
Do people really think ZNWD have chewed through 18.75m in 11 months?
Stick to the facts - not the fiction some posters promote.
GLA.
Stephen11.
So glad i didn't sleep in this morning and got in early.
Brilliant RNS 😀.
It will be interesting to see what the SP opens at.
GLA.
Stephen11.
Hargreaves Lansdown Asset Management Ltd.
5,477,000 4.202 % 444 623 p
IG Markets Ltd.
2,735,000 2.098 % 222 027 p
Rathbones Investment Management Ltd.
2,345,000 1.799 % 190 367 p
HSBC Global Asset Management (UK) Ltd.
2,205,000 1.692 % 179 002 p
Walker Crips Investment Management Ltd.
1,895,000 1.454 % 153 836 p
Unicorn Asset Management Ltd.
1,154,697 0.8858 % 93 738 p
Octopus Investments Ltd.
622,309 0.4774 % 50 519 p
Peel Hunt LLP
617,000 0.4733 % 50 088 p
Ian Gilham
614,295 0.4713 % 49 868 p
Evelyn Partners Investment Management Services Ltd.
500,000 0.3836 % 40 590 p
Lionel1,
Thankyou for sharing the NICE guidance document. Have we any way of knowing or finding out on what date the amendments were actioned.
I reviewed all 14 pages - the EAG are a hard audience to influence.
I did find one point, made by GDR very interesting, and an obvious selling points to Health Trusts around the world - as below:
"The early economic model assumes that the test will require 30 minutes of nursing time to implement each diagnostic test. This is costed at £28 with a sensitivity analysis (low-high) of £15-40. Even allowing for variation in practice across other (some smaller) centres, this is highly likely to represent a significant overestimate. Based on extensive consultation with NICU nursing colleagues who use the genedrive RNR1 platform in clinical practice, we are aware that the system has a “hands on” time of approximately 3-4 minutes. The nurse is not required to remain with the system whilst it is in operation and returns for 1-2 minutes once the results are available."
In a nutshell - the test takes a nurse 6 minutes to perform and check the results, and not 30 minutes.
It's all about health economics nowadays so this is a great selling point GDR should be shouting from the rooftops!
GLA.
Stephen11.
Hi Muminr,
Rightly or wrongly I've used some profit gained elsewhere and averaged down to the low 10s. I think things will come good eventually, although this can be a most frustrating share to hold at times (as with all new to market pharma stocks). That said, if Mr Cheek holds to his word we should hear some better news starting to flow in February and March this year.
GLA.
Stephen11.